Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$26.24 - $39.63 $2.87 Million - $4.34 Million
-109,562 Reduced 66.4%
55,443 $2.18 Million
Q1 2023

May 15, 2023

BUY
$18.67 - $24.56 $953,178 - $1.25 Million
51,054 Added 30.94%
216,059 $5.26 Million
Q4 2022

Aug 11, 2023

BUY
$17.24 - $23.95 $333,611 - $463,456
19,351 Added 13.29%
165,005 $3.53 Million
Q4 2022

Feb 13, 2023

BUY
$17.24 - $23.95 $333,611 - $463,456
19,351 Added 13.29%
165,005 $3.53 Million
Q3 2022

Aug 11, 2023

SELL
$9.4 - $18.59 $240,950 - $476,517
-25,633 Reduced 14.96%
145,654 $2.61 Million
Q3 2022

Nov 03, 2022

SELL
$9.4 - $18.59 $240,950 - $476,517
-25,633 Reduced 14.96%
145,654 $2.55 Million
Q2 2022

Aug 11, 2023

SELL
$9.12 - $18.9 $40,191 - $83,292
-4,407 Reduced 2.51%
171,287 $1.65 Million
Q2 2022

Aug 15, 2022

SELL
$9.12 - $18.9 $40,191 - $83,292
-4,407 Reduced 2.51%
171,287 $1.66 Million
Q1 2022

Aug 11, 2023

SELL
$12.15 - $16.83 $490,434 - $679,342
-40,365 Reduced 18.68%
175,694 $2.96 Million
Q1 2022

May 20, 2022

BUY
$12.15 - $16.83 $1.44 Million - $2 Million
118,678 Added 208.15%
175,694 $2.89 Million
Q4 2021

Feb 16, 2022

BUY
$13.83 - $18.78 $56,758 - $77,073
4,104 Added 7.76%
57,016 $942,000
Q3 2021

Nov 12, 2021

BUY
$7.07 - $17.5 $2,806 - $6,947
397 Added 0.76%
52,912 $859,000
Q2 2021

Aug 12, 2021

BUY
$5.69 - $7.17 $37,184 - $46,855
6,535 Added 14.21%
52,515 $331,000
Q1 2021

May 03, 2021

SELL
$5.08 - $6.89 $12,664 - $17,176
-2,493 Reduced 5.14%
45,980 $284,000
Q4 2020

Feb 12, 2021

BUY
$5.65 - $7.66 $17,904 - $24,274
3,169 Added 6.99%
48,473 $335,000
Q3 2020

Nov 09, 2020

BUY
$4.01 - $6.29 $69,276 - $108,666
17,276 Added 61.64%
45,304 $256,000
Q2 2020

Aug 10, 2020

BUY
$3.06 - $6.6 $85,765 - $184,984
28,028 New
28,028 $150,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.